UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )

 

Filed by the Registrant ☒
Filed by a Party other than the Registrant ☐

Check the appropriate box:
☐    Preliminary Proxy Statement
☐    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐    Definitive Proxy Statement
☒    Definitive Additional Materials
☐    Soliciting Material Pursuant to §240.14a-12
Tourmaline Bio, Inc.
(Name of Registrant as Specified In Its Charter)

N/A
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
☒    No fee required.
☐    Fee paid previously with preliminary materials.
☐    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11





trmlnoticepage1.jpg


trmlnoticepage2.jpg


Talaris Therapeutics (NASDAQ:TALS)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024 Talaris Therapeutics 차트를 더 보려면 여기를 클릭.
Talaris Therapeutics (NASDAQ:TALS)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024 Talaris Therapeutics 차트를 더 보려면 여기를 클릭.